LATENTIATED PRODRUG APPROACH OF DRUGS: AN OVERVIEW

Authors

  • DHARUN P. R. Crescent School of Pharmacy, B.S Abdur Rahman Crescent Institute of Science and Technology, Chennai, Tamil Nadu 600048, India
  • ISMAIL Y. Crescent School of Pharmacy, B.S Abdur Rahman Crescent Institute of Science and Technology, Chennai, Tamil Nadu 600048, India
  • VIJAYA VARA PRASAD M. Crescent School of Pharmacy, B.S Abdur Rahman Crescent Institute of Science and Technology, Chennai, Tamil Nadu 600048, India

DOI:

https://doi.org/10.22159/ijap.2021v13i6.42794

Keywords:

Prodrug, Carriers, Enzymes, Strategies, Specificity, Chemotherapy.

Abstract

Prodrugs, with their capability of declining the adverse events and elevating the bioavailability of certain drugs, have captured enormous attention throughout the world since the 20th century. The versatility of the prodrugs that are inert and after administration releasing the parent moiety for the desired effect has become a major criterion for the scientists to incorporate this to alleviate the undesired effects of a conventional drug. About 10% of the prevailing drugs are prodrugs and their usage is being amplified owing to its critical application in cancer therapy, toxicity alleviation, and specificity. The purpose of this review is to understand the prodrugs, strategies incorporated in designing the prodrugs, applications, their crucial benefits in targeted action at a specific site of the body, their advantageous effects in chemotherapy. Also, to be acknowledged with the ongoing clinical trials and researches on prodrugs and some notable marketed prodrugs in a depth manner.

Downloads

Download data is not yet available.

References

Stella VJ, Charman WN, Naringrekar VH. Prodrugs. Drugs 1985;29:455-73.

Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Järvinen T, et al. Prodrugs: design and clinical applications. Nature reviews Drug discovery 2008;7:255-70.

Rautio J, Meanwell NA, Di L, Hageman MJ. The expanding role of prodrugs in contemporary drug design and development. Nature Reviews Drug Discovery 2018;17:559-87.

Han HK, Amidon GL. Targeted prodrug design to optimize drug delivery. Aaps Pharmsci 2000;2:48-58.

Yu LX, Straughn AB, Faustino PJ, Yang Y, Parekh A, Ciavarella AB, et al. The effect of food on the relative bioavailability of rapidly dissolving immediate-release solid oral products containing highly soluble drugs. Molecular pharmaceutics 2004;1:357-62.

Surendran V, Singh A, Sampathkumar KP. Synthesis and characterization of novel amino acid prodrug of famotidine. Int J Pharm Pharm Sci 2015;7:403-8..

Gomes P, Vale N, Moreira R. Cyclization-activated prodrugs. Molecules 2007;12:2484-506.

Zawilska JB, Wojcieszak J, Olejniczak AB. Prodrugs: a challenge for the drug development. Pharmacological reports 2013;65:1-4.

Huttunen KM, Raunio H, Rautio J. Prodrugs—from serendipity to rational design. Pharmacological reviews 2011;63:750-71.

Das N, Dhanawat M, Dash B, Nagarwal RC, Shrivastava SK. Codrug: An efficient approach for drug optimization. European Journal of Pharmaceutical Sciences 2010;41:571-88.

Wu KM. A new classification of prodrugs: regulatory perspectives. Pharmaceuticals 2009;2:77-81.

Testa B, Mayer JM, Mayer J. Hydrolysis in drug and prodrug metabolism. John Wiley & Sons;2003.

Karaman R. Prodrugs Design Based on Inter‐and Intramolecular Chemical Processes. Chemical biology & drug design 2013;82:643-68.

Clas SD, Sanchez RI, Nofsinger R. Chemistry-enabled drug delivery (prodrugs): recent progress and challenges. Drug discovery today 2014;19:79-87.

Lai WF, editor. Systemic Delivery Technologies in Anti-Aging Medicine: Methods and Applications. Springer International Publishing;2020.

Karaman R, Fattash B, Qtait A. The future of prodrugs–design by quantum mechanics methods. Expert opinion on drug delivery 2013;10:713-29.

Karaman R. Prodrugs design by computation methods-a new era. Journal of Drug Designing 2013;1:e113.

Karaman R. Prodrug design vs drug design. J Drug Design 2013;2:e114.

Papot S, Tranoy I, Tillequin F, Florent J, Gesson J. Design of selectively activated anticancer prodrugs: elimination and cyclization strategies. Current Medicinal Chemistry-Anti-Cancer Agents 2002;2:155-85.

Chen XQ, Venkatesh S. Miniature device for aqueous and non-aqueous solubility measurements during drug discovery. Pharmaceutical research 2004;21:1758-61.

Liu HF, Wan N, Huan ML, Jia YY, Yuan XF, Zhou SY, et al. Enhanced water-soluble derivative of PC407 as a novel potential COX-2 inhibitor injectable formulation. Bioorganic & medicinal chemistry letters 2014;24:4794-7.

Jornada DH, dos Santos Fernandes GF, Chiba DE, De Melo TR, Dos Santos JL, Chung MC. The prodrug approach: A successful tool for improving drug solubility. Molecules 2016;21:42.

Draganov DI, La Du BN. Pharmacogenetics of paraoxonases: a brief review. Naunyn-Schmiedeberg's archives of pharmacology 2004;369:78-88.

Testa B. Prodrugs: bridging pharmacodynamic/pharmacokinetic gaps. Current opinion in chemical biology 2009;13:338-44.

Glazko AJ, Edgerton WH, Dill WA, Lenz WR. Chloromycetln Palmitate-a Synthetic Ester of Chloromycetin. Antibiotics & Chemotherapy 1952;2:234-42.

Sinkula AA, Morozowich W, Rowe EL. Chemical modification of clindamycin: synthesis and evaluation of selected esters. Journal of pharmaceutical sciences 1973;62:1106-11.

Clark Jr RK, Varner EL. New esters of erythromycin. Antibiotics & chemotherapy (Northfield, Ill.) 1957;7:487-9.

Bundy GL, inventor; Upjohn Co., assignee. Bioprecursors of 9-deoxy-6, 9α-nitrilo-PGF1. United States patent US 4151176. 1979 Apr 24.

Morozowich W, Lamb DJ, Karnes HA, Mackellar FA, Lewis C, Stern KF, et al. Synthesis and bioactivity of lincomycin-2-phosphate. Journal of pharmaceutical sciences 1969;58:1485-9.

Morozowich W, Sinkula AA, MacKellar FA, Lewis C. Synthesis and bioactivity of lincomycin 2-monoesters. Journal of pharmaceutical sciences 1973;62:1102-5.

Gruber Jr CM, Stephens VC, Terrill PM. Propoxyphene napsylate: Chemistry and experimental design. Toxicology and applied pharmacology 1971;19:423-6.

AJ G, He C, LM W, TF R. Succinic acid esters of chloramphenicol. Antibiotics annual 1957;5:792-802.

Edmondson HT. Parenteral and oral clindamycin therapy in surgical infections: a preliminary report. Annals of surgery 1973;178:637.

Gray JE, Weaver RN, Moran J, Feenstra ES. The parenteral toxicity of clindamycin 2-phosphate in laboratory animals. Toxicology and applied pharmacology 1974;27:308-21.

DeHAAN RM, METZLER CM, SCHELLENBERG D, VANDENBOSCH WD. Pharmacokinetic studies of clindamycin phosphate. The Journal of Clinical Pharmacology and New Drugs 1973;13:190-209.

Bundgaard H. Spectrophotometric determination of ampicillin sodium in the presence of its degradation and polymerization products. Journal of Pharmacy and Pharmacology 1974;26:385-92.

Schwartz MA, Hayton WL. Relative stability of hetacillin and ampicillin in solution. Journal of pharmaceutical sciences 1972;61:906-9.

Ho NF, Park JY, Morozowich W, Higuchi WI. Physical model approach to the design of drugs with improved intestinal absorption. Design of biopharmaceutical properties through prodrugs and analogs 1977:136-227.

Jana S, Mandlekar S, Marathe P. Prodrug design to improve pharmacokinetic and drug delivery properties: challenges to the discovery scientists. Current medicinal chemistry 2010;17:3874-908.

Halen PK, Murumkar PR, Giridhar R, Yadav MR. Prodrug designing of NSAIDs. Mini reviews in medicinal chemistry 2009;9:124-39.

Friend DR, Chang GW. A colon-specific drug-delivery system based on drug glycosides and the glycosidases of colonic bacteria. Journal of medicinal chemistry 1984;27:261-6.

Stella VJ, Himmelstein KJ. Critique of prodrugs and site specific delivery. InOptimization of Drug Delivery. Alfred Benzon Symposium Copenhagen: Munksgaard 1982:134-155.

Wermuth CG. Designing prodrugs and bioprecursors. In The practice of medicinal chemistry. Academic Press 2008:721-746.

Ettmayer P, Amidon GL, Clement B, Testa B. Lessons learned from marketed and investigational prodrugs. Journal of medicinal chemistry 2004;47:2393-404.

Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood–brain barrier. Neurobiology of disease 2010;37:13-25.

Anderson BD. Prodrugs for improved CNS delivery. Advanced drug delivery reviews 1996;19:171-202.

Pardridge WM. Brain drug development and brain drug targeting. Pharmaceutical Research 2007;24:1729-1732.

Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF. Getting into the brain. CNS drugs 2009;23:35-58.

Warren MS, Rautio J, editors. Prodrugs and Targeted Delivery. Wiley-VCH; 2011.

Brogden RN, Speight TM, Avery GS. Levodopa: A review of its pharmacological properties and therapeutic uses with particular reference to Parkinsonism. Drugs 1971;2:262-400.

Van Montfoort JE, Hagenbuch B, Groothuis GM, Koepsell H, Meier PJ, Meijer DK. Drug uptake systems in liver and kidney. Current drug metabolism 2003;4:185-211.

Erion MD, Bullough DA, Lin CC, Hong Z. HepDirect prodrugs for targeting nucleotide-based antiviral drugs to the liver. Current opinion in investigational drugs (London, England: 2000) 2006;7:109-17.

Li F, Maag H, Alfredson T. Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. Journal of pharmaceutical sciences 2008;97:1109-34.

Lin CC, Yeh LT, Vitarella D, Hong Z, Erion MD. Remofovir mesylate: a prodrug of PMEA with improved liver-targeting and safety in rats and monkeys. Antiviral Chemistry and Chemotherapy 2004;15:307-17.

Reddy KR, Colby TJ, Fujitaki JM, van Poelje PD, Erion MD. Liver Targeting of Hepatitis-B Antiviral Lamivudine Using the HepDirect™ Prodrug Technology. Nucleosides, Nucleotides and Nucleic Acids 2005;24:375-81.

Sinha VR, Kumria R. Colonic drug delivery: prodrug approach. Pharmaceutical research 2001;18:557-64.

Minami K, Hirayama F, Uekama K. Colon-specific drug delivery based on a cyclodextrin prodrug: release behavior of biphenylylacetic acid from its cyclodextrin conjugates in rat intestinal tracts after oral administration. Journal of pharmaceutical sciences 1998;87:715-20.

Kumar SU, Tyagi DK, Gupta AR. Synthesis, characterization and pharmcological activity of ester prodrugs of naproxen. Asian Journal of Pharmaceutical and Clinical Research 2010;3:208-11.

Valia KH, Tojo K, Chien YW. Long-term permeation kinetics of estradiol:(III) kinetic analyses of the simultaneous skin permeation and bioconversion of estradiol esters. Drug Development and Industrial Pharmacy 1985;11:1133-73.

Fang JY, Leu YL. Prodrug strategy for enhancing drug delivery via skin. Current drug discovery technologies 2006;3:211-24.

Ar C, Preeti M Gandhi. Synthesis and evaluation of amino acid ester conjugates of hiv protease inhibitor. Asian Journal of Pharmaceutical and Clinical Research 2019;12:342-6.

Devarajan-Ketha H, Sloan KB. N, N′-Dialkylaminoalkylcarbonyl (DAAC) prodrugs and aminoalkylcarbonyl (AAC) prodrugs of 4-hydroxyacetanilide and naltrexone with improved skin permeation properties. Bioorganic & medicinal chemistry letters 2011;21:4078-82.

Mahato R, Tai W, Cheng K. Prodrugs for improving tumor targetability and efficiency. Advanced drug delivery reviews 2011;63:659-70.

Groot FM, Damen EW, Scheeren HW. Anticancer prodrugs for application in monotherapy targeting hypoxia, tumor-associated enzymes, and receptors. Current medicinal chemistry 2001;8:1093-122.

Kavanaugh WM. Antibody prodrugs for cancer. Expert opinion on biological therapy 2020;20:163-71.

Giang I, Boland EL, Poon GM. Prodrug applications for targeted cancer therapy. The AAPS journal 2014;16:899-913.

Johnston PG, Kaye S. Capecitabine: a novel agent for the treatment of solid tumors. Anti-cancer drugs 2001;12:639-46.

Koukourakis GV, Kouloulias V, Koukourakis MJ, Zacharias GA, Zabatis H, Kouvaris J. Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review. Molecules 2008;13:1897-922.

Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. European journal of cancer 1998;34:1274-81.

Zhang JZ, Bonnitcha P, Wexselblatt E, Klein AV, Najajreh Y, Gibson D, et al. Facile preparation of mono-, di-and mixed-carboxylato platinum (IV) complexes for versatile anticancer prodrug design. Chem. Eur. J 2013;19:1672-6.

Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nature Reviews Cancer 2009;9:576-86.

Sánchez-Sánchez L, Cadena-Nava RD, Palomares LA, Ruiz-Garcia J, Koay MS, Cornelissen JJ, et al. Chemotherapy pro-drug activation by biocatalytic virus-like nanoparticles containing cytochrome P450. Enzyme and microbial technology 2014;60:24-31.

Xu Z, Wang D, Xu S, Liu X, Zhang X, Zhang H. Preparation of a Camptothecin Prodrug with Glutathione‐Responsive Disulfide Linker for Anticancer Drug Delivery. Chemistry–An Asian Journal 2014;9:199-205.

Xu G, McLeod HL. Strategies for enzyme/prodrug cancer therapy. Clinical Cancer Research 2001;7:3314-24.

Chari RV. Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy. Advanced drug delivery reviews 1998;31:89-104.

Bagshawe KD, Sharma SK, Begent RH. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Expert opinion on biological therapy 2004;4:1777-89.

Singh PP, Joshi S, Russell PJ, Verma ND, Wang X, Khatri A. Molecular chemotherapy and chemotherapy: a new front against late-stage hormone-refractory prostate cancer. Clinical Cancer Research 2011;17:4006-18.

Altaner C. Prodrug cancer gene therapy. Cancer letters 2008;270:191-201.

Stella VJ. Prodrugs as therapeutics. Expert Opinion on Therapeutic Patents 2004;14:277-280.

Markovic M, Ben-Shabat S, Dahan A. Prodrugs for Improved Drug Delivery: Lessons Learned from Recently Developed and Marketed Products. Pharmaceutics 2020;12:1031.

Hale JJ, Mills SG, MacCoss M, Dorn CP, Finke PE, Budhu RJ, et al. Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs. Journal of medicinal chemistry 2000;43:1234-41.

Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert opinion on pharmacotherapy 2008;9:1787-96.

Stella VJ, Zygmunt JJ, Georg IG, Safadi MS, inventors; University of Kansas., assignee. Water soluble prodrugs of hindered alcohols. United States patent US 6872838. 2005 Mar 29.

Kumpulainen H, Järvinen T, Mannila A, Leppänen J, Nevalainen T, Mäntylä A, et al. Synthesis, in vitro and in vivo characterization of novel ethyl dioxy phosphate prodrug of propofol. European journal of pharmaceutical sciences 2008;34:110-7.

Dobesh PP. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2009;29:1089-102.

VanderMolen KM, McCulloch W, Pearce CJ, Oberlies NH. Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. The Journal of antibiotics 2011;64:525-31.

Adachi K, Chiba K. FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology. Perspectives in medicinal chemistry 2007;1:1177391X0700100002.

Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. British journal of clinical pharmacology 2007;64:292-303.

Ishikawa T, Matsunaga N, Tawada H, Kuroda N, Nakayama Y, Ishibashi Y, et al. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Bioorganic & medicinal chemistry 2003;11:2427-37.

Kurtz TW, Kajiya T. Differential pharmacology and benefit/risk of azilsartan compared to other sartans. Vascular health and risk management 2012;8:133.

Cundy KC, Branch R, Chernov-Rogan T, Dias T, Estrada T, Hold K, et al. XP13512 [(±)-1-([(α-Isobutanoyloxyethoxy) carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. Journal of Pharmacology and experimental therapeutics 2004;311:315-23.

Stappaerts J, Geboers S, Snoeys J, Brouwers J, Tack J, Annaert P, et al. Rapid conversion of the ester prodrug abiraterone acetate results in intestinal supersaturation and enhanced absorption of abiraterone: in vitro, rat in situ and human in vivo studies. European Journal of Pharmaceutics and Biopharmaceutics 2015;90:1-7.

Fukano Y, Kawazu K. Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to rats. Drug metabolism and disposition 2009;37:1622-34.

Hoy SM. Tafluprost/Timolol: a review in open-angle glaucoma or ocular hypertension. Drugs 2015;75:1807-13.

Linker RA, Haghikia A. Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy. Therapeutic advances in chronic disease 2016;7:198-207.

Benes J, Parada A, Figueiredo AA, Alves PC, Freitas AP, Learmonth DA, et al. Anticonvulsant and sodium channel-blocking properties of novel 10, 11-dihydro-5 H-dibenz [b, f] azepine-5-carboxamide derivatives. Journal of Medicinal Chemistry 1999;42:2582-7.

Ben-Menachem E. Eslicarbazepine acetate: a well-kept secret?. Epilepsy Currents 2010;10:7-8.

Sofia MJ, Bao D, Chang W, Du J, Nagarathnam D, Rachakonda S, et al. Discovery of a β-d-2′-deoxy-2′-α-fluoro-2′-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. Journal of medicinal chemistry 2010;53:7202-18.

Goldstein DS. L‐dihydroxyphenylserine (L‐DOPS): a norepinephrine prodrug. Cardiovascular drug reviews 2006;24:189-203.

Vera-Cabrera L, Gonzalez E, Rendon A, Ocampo-Candiani J, Welsh O, Velazquez-Moreno VM, et al. In vitro activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis. Antimicrobial agents and chemotherapy 2006;50:3170-2.

Ohwada J, Tsukazaki M, Hayase T, Oikawa N, Isshiki Y, Fukuda H, et al. Design, synthesis and antifungal activity of a novel water-soluble prodrug of antifungal triazole. Bioorganic & medicinal chemistry letters 2003;13:191-6.

Ksander GM, Ghai RD, deJesus R, Diefenbacher C, Yuan A, Berry C, et al. Dicarboxylic acid dipeptide neutral endopeptidase inhibitors. Journal of medicinal chemistry 1995;38:1689-700.

Von Borstel RW, Bamat MK, inventors; Pro-Neuron.inc., assignee. Acylated uridine and cytidine and uses thereof. Patent WO 89/03837. 1989 May 5.

Raedler LA. Aripiprazole lauroxil (Aristada): long-acting atypical antipsychotic injection approved for the treatment of patients with schizophrenia. American health & drug benefits 2016;9:40.

Ballatore C, McGuigan C, De Clercq E, Balzarini J. Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA. Bioorganic & medicinal chemistry letters 2001;11:1053-6.

Eisenberg EJ, He GX, Lee WA. Metabolism of GS-7340, a novel phenyl monophosphoramidate intracellular prodrug of PMPA, in blood. Nucleosides, Nucleotides and Nucleic Acids 2001;20:1091-8.

Elliott EL, Ferdous AJ, Kaufman MJ, Komar SA, Mazaik DL, McCubbin QJ, et al, inventors. Boronate ester compounds and pharmaceutical compositions thereof. United States patent US 12/485344. 2009 Dec 31.

Nakamura A, Yamada T, Asaki T. Synthesis and evaluation of N-acylsulfonamide and N-acylsulfonylurea prodrugs of a prostacyclin receptor agonist. Bioorganic & medicinal chemistry 2007;15:7720-5.

Asaki T, Kuwano K, Morrison K, Gatfield J, Hamamoto T, Clozel M. Selexipag: an oral and selective IP prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. J. Med. Chem 2015;58:7128-7137.

Möllmann H, Hochhaus G, Rohatagi S, Barth J, Derendorf H. Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. Pharmaceutical research 1995;12:1096-100.

Liu Q, Yang Q, Sun W, Vogel P, Heydorn W, Yu XQ, et al. Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract. Journal of Pharmacology and Experimental Therapeutics 2008;325:47-55.

O'Brien CF, Jimenez R, Hauser RA, Factor SA, Burke J, Mandri D, et al. NBI‐98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double‐blind, placebo‐controlled study. Movement Disorders 2015;30:1681-7.

Hall BS, Wilkinson SR. Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation. Antimicrobial agents and chemotherapy 2012;56:115-23.

Garcia GA, Ngai P, Mosaed S, Lin KY. Critical evaluation of latanoprostene bunod in the treatment of glaucoma. Clinical Ophthalmology (Auckland, NZ) 2016;10:2035.

Gillis JC, Wiseman LR. Secnidazole. Drugs 1996;51:621-38.

Sun X, Vilar S, Tatonetti NP. High-throughput methods for combinatorial drug discovery. Science translational medicine 2013;5:205rv1.

de Albuquerque Silva AT, Chung MC, Castro LF, Carvalho Guido RV, Ferreira EI. Advances in prodrug design. Mini reviews in medicinal chemistry 2005;5:893-914.

Stella VJ, Nti-Addae KW. Prodrug strategies to overcome poor water solubility. Advanced drug delivery reviews 2007;59:677-94.

Stella VJ. Prodrug approaches to enhancing the oral delivery of poorly permeable drugs. InProdrugs Springer 2007:37-82.

Dahan A, Khamis M, Agbaria R, Karaman R. Targeted prodrugs in oral drug delivery: the modern molecular biopharmaceutical approach. Expert opinion on drug delivery 2012;9:1001-13.

Dahan A, Markovic M, Aponick A, Zimmermann EM, Ben-Shabat S. The prospects of lipidic prodrugs: an old approach with an emerging future. Future medicinal chemistry 2019;11:2563-71.

Markovic M, Ben-Shabat S, Aponick A, Zimmermann EM, Dahan A. Lipids and lipid-processing pathways in drug delivery and therapeutics. International journal of molecular sciences 2020;21:3248.

Markovic M, Ben‐Shabat S, Keinan S, Aponick A, Zimmermann EM, Dahan A. Lipidic prodrug approach for improved oral drug delivery and therapy. Medicinal research reviews 2019;39:579-607.

Markovic M, Ben-Shabat S, Dahan A. Computational simulations to guide enzyme-mediated prodrug activation. International Journal of Molecular Sciences 2020;21:3621.

Markovic M, Ben-Shabat S, Keinan S, Aponick A, Zimmermann EM, Dahan A. Molecular modeling-guided design of phospholipid-based prodrugs. International journal of molecular sciences 2019;20:2210.

Markovic M, Dahan A, Keinan S, Kurnikov I, Aponick A, Zimmermann EM, et al. Phospholipid-based prodrugs for colon-targeted drug delivery: Experimental study and in-silico simulations. Pharmaceutics 2019;11:186.

McNamara MG, Goyal L, Doherty M, Springfeld C, Cosgrove D, Sjoquist KM, et al. NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide: 121). Future Oncology 2020;16:1069-81.

Evans K, Duan J, Pritchard T, Jones CD, McDermott L, Gu Z, et al. OBI-3424, a novel AKR1C3-activated prodrug, exhibits potent efficacy against preclinical models of T-ALL. Clinical Cancer Research 2019;25:4493-503.

Alanazi AS, James E, Mehellou Y. The ProTide prodrug technology: where next?. ACS Med. Chem. Lett 2019;10:2−5

Arora M, Bogenberger JM, Abdelrahman A, Leiting JL, Chen X, Egan JB, et al. Evaluation of NUC-1031: A first-in-class ProTide in biliary tract cancer. Cancer chemotherapy and pharmacology 2020;85:1063-78.

Markovic M, Ben-Shabat S, Dahan A. Prodrugs for Improved Drug Delivery: Lessons Learned from Recently Developed and Marketed Products. Pharmaceutics 2020;12:1031.

Mullard, A. 2018 FDA drug approvals. Nat. Rev. Drug Discov 2019;18:85–89.

Hendaus MA. Remdesivir in the treatment of coronavirus disease 2019 (COVID-19): a simplified summary. Journal of Biomolecular Structure and Dynamics 2020;19:1-6.

Published

06-09-2021

How to Cite

P. R., D., Y., I., & PRASAD M., V. V. (2021). LATENTIATED PRODRUG APPROACH OF DRUGS: AN OVERVIEW. International Journal of Applied Pharmaceutics, 13(6). https://doi.org/10.22159/ijap.2021v13i6.42794

Issue

Section

Review Article(s)